Would you consider adding abiraterone, in addition to ADT, for patients with less than very-high risk localized prostate cancer but high clinical-genomic metastasis risk after EBRT?
Specifically if metastatic risk estimate approached the failure rate in control arm of STAMPEDE for high-risk non-metastatic disease (69% MFS at 6 years).
Answer from: Medical Oncologist at Academic Institution
This is a very tricky area to be sure. The short answer is yes, I do in carefully selected patients.It is well established that genomics correlates with biology in the mHSPC and mCRPC settings. Now, there is emerging data that genomics correlates well with biology in the localized disease setting (e...
Sign in or Register to read more